We have not reviewed the charts of United Therapeutics Corporation (UTHR) since Dec. 8, 2017 and then we had a long-term Point and Figure target of $175. Prices finally reached that long-term price target this year.
More from Investing
I remain convinced that we can't begin to talk about a bottom in the indexes until the S&P 500 is in a technical bear market.
Some investors may be asking whether we're seeing another 'nail in the coffin' of the secular bull market as several transport names get downgraded. Let's not ... go off the rails.